Failure of megestrol acetate to reverse tamoxifen induced endometrial neoplasia: Two case reports

International Journal of Gynecological Cancer

Volumn 9, Issue 5, 1999, Pages 362-364

  Rose, P G ^a   Brandewie, E V ^b   Abdul Karim, F W ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Endometrial neoplasia; Megestrol acetate; Tamoxifen

Indexed keywords

MEGESTROL ACETATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CASE REPORT; DRUG INDUCED DISEASE; ENDOMETRIUM TUMOR; FEMALE; HUMAN; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0032742394     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99041.x     Document Type: Article

References (14)

1. Jaiyesimi IA, Budzar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995;13:513-29.
2. Killacke MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
3. Fornander T, Cedermark B, Mattsson A et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;ii:117-20.
4. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-7.
5. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86: 527-37.
6. Kommoss F, Karck U, Prompeler H, Pfisterer J, Kirkpatrick CJ. Steroid expression in endometria from women treated with tamoxifen. Gynecol Oncol 1998;70:188-91.
7. Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gyecol 1983;146:316-22.
8. Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS. Can primary endometrial carcinoma be treated without surgery and radiation therapy? Gynecol Oncol 1985;20: 139-55.
9. Cuenca RE, Giachino J, Arrendoondo MA. Endometrial carcinoma associated with breast cancer. Cancer 1996;77: 2058-63.
10. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gyn Rep Biol 1990;35:235-8.
11. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy, Int J Gynecol Obstet 1991;36:127-30.
12. Kuiper GGJM, Enmark E, Puelto-Huiko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in the rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:2925-30.
13. Watanabe T, Inoue S, Ogawa S et al. Agonist effect of tamoxifen is dependent on cell type, ERE-promoter content, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Com 1997;236:140-5.
14. Muss HB, Case D, Atkins JN et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 1994;12:1630-8.